Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma

NCT02659020 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02659020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02659020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Completed
Start date
March 1, 2016
Completion date
April 27, 2021
Enrollment
310 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma